A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation-Reference-Cited by-同舟云学术

A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation

Published:2017-10-08 Issue:3 Volume:26 Page:1013-1016
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Zecchini Julia,Yum Kendra,Steinberg Amir,Smith Cardinale,Kim Sara

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/article/10.1007/s00520-017-3923-1/fulltext.html

Reference13 articles.

1. Maschmeyer G, Rolston K. Myeloid growth factors. Infections in Hematology. Springer Berlin Heidelberg: 2015

2. Nahon S et al (2016) Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicenter study. Support Care Cancer 24:1991–1998

3. Elayan MM et al (2015) Tbo-filgrastim versus filgrastim during mobilization and neutrophil engraftment for autologous stem cell transplantation. Biol Blood Marrow Transplant 21:1921–1925

4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: myeloid growth factors. Version 1.2017. NCCN.org

5. Renwick W, Pettengell R, Green M (2009) Use of filgrastim and pegfilgrastim to support delivery of chemotherapy. BioDrugs 23:175–186

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filgrastim biosimilar (EP2006): A review of 15 years’ post-approval evidence;Critical Reviews in Oncology/Hematology;2024-04

2. Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars;Expert Opinion on Pharmacotherapy;2021-02-12

3. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020;Journal of the National Comprehensive Cancer Network;2020-01